Congress Scientific Watch

From 64th ASH Annual Meeting and Exposition:
A study of patients aged up to 65 years with treatment-naïve mantle cell lymphoma supports the use of ibrutinib alongside chemotherapy and autologous stem cell transplantation

From San Antonio Breast Cancer Symposium 2022:
Women with early-stage, hormone receptor-positive breast cancer can be reassured that interrupting endocrine therapy to attempt pregnancy does not significantly increase their risk for disease recurrence in the short term

From San Antonio Breast Cancer Symposium 2022:
The CAPItello-291 trial adds support for use of capivasertib plus fulvestrant for the treatment of advanced breast cancer patients who have progressed after endocrine-based therapy

From the 64th American Society of Hematology Annual Meeting:
Phase I/II trial data point to the promising efficacy and tolerability of the GPRC5D- and CD3-targeted agent talquetamab in heavily pretreated patients with relapsed or refractory multiple myeloma

From ESMO Immuno-Oncology Congress 2022:
A monoclonal antibody treatment given with GM-CSF has achieved objective responses and durable survival outcomes for high-risk refractory or relapsed neuroblastoma and residual bone disease

From San Antonio Breast Cancer Symposium 2022:
Patients with oestrogen receptor-positive, HER2-negative advanced breast cancer have better progression-free survival with camizestrant than with fulvestrant

From San Antonio Breast Cancer Symposium 2022:
The phase II TRIO-US B-12 TALENT clinical trial has shown that people with hormone-receptor-positive, HER2-low localised breast cancer may benefit from neoadjuvant trastuzumab deruxtecan

From San Antonio Breast Cancer Symposium 2022:
Two phase III trials show that trastuzumab deruxtecan prolongs survival relative to trastuzumab emtansine or chemotherapy in previously treated women with HER2-positive metastatic breast cancer

From ESMO Immuno-Oncology Congress 2022:
Dostarlimab plus chemotherapy has achieved an objective response rate in metastatic non-small-cell lung cancer comparable to that of pembrolizumab plus chemotherapy

From San Antonio Breast Cancer Symposium 2022:
For women with aggressive hormone receptor-positive, HER2-negative advanced breast cancer, first-line ribociclib plus endocrine therapy offers better progression-free survival than combination chemotherapy

From EBCC 2022:
Indirect trial comparison suggests an overall survival advantage with ribociclib over palbociclib in combination with endocrine therapy for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer

From EBCC 2022:
Neoadjuvant therapy achieves a complete response in the ductal carcinoma in situ component of invasive breast cancer in approximately half of cases